1. In this randomized controlled trial, vepdegestrant achieved a longer progression-free survival than fulvestrant in patients with advanced ER-positive, HER2-negative ...
1. In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
Click to read this study in Journal of Clinical Oncology.
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients ...
Click to read this study in Lancet Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in The Lancet Oncology.
Click to read the study in European Journal of Cancer
